Overview

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Status:
Completed

Trial end date:
2019-01-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen Research (Munich) GmbH

Treatments:

Antibodies, Bispecific
Blinatumomab